CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • November 10th, 2014 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
This MANUFACTURING SERVICES AGREEMENT (the “Agreement”) is made and entered into as of September 2, 2014 (the “Effective Date”) by and between Orexigen Therapeutics, Inc., a Delaware corporation with its principal place of business at 3344 N. Torrey Pines Court, Suite 200, La Jolla, California 92037, United States of America (“Orexigen”), and Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan, with its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, 540-8645, Japan (“Takeda”). Orexigen and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
